Table 2.

The summary of the most important current clinical trials with targeted therapy and immune checkpoint inhibitors in sequential treatment.

Study/Phase	Key Inclusion Criteria and Drug Sequence	Primary Endpoint	Key Secondary Endpoints
SWITCH Phase III	Stage III (unresectable) or stage IV disease Presence of BRAFV600E or V600K mutation in tumor tissue prior to enrolmen ECOG PS 0–1 Nivolumab + ipilimumab with nivolumab maintenance followed by dabrafenib + trametinib at PD or dabrafenib + trametinib followed by nivolumab + ipilimumab with nivolumab maintenance at PD	•  OS	PFS Response rate Safety
SECOMBIT Phase II	Stage III (unresectable) or stage IV melanoma Treatment-naïve patients Presence of BRAFV600E or V600K mutation in tumor tissue prior to enrolment ECOG PS 0–1 Encorafenib + binimetinib followed by nivolumab + ipilimumab with nivolumab maintenance at PD or nivolumab + ipilimumab with nivolumab maintenance followed by encorafenib + binimetinib at PD or encorafenib + binimetinib for 8 weeks with a switch to nivolumab + ipilimumab with nivolumab maintenance followed by encorafenib + binimetinib at PD	•  OS	PFS 2/3-YS Best ORR DOR Safety QoL
EORTC EBIN Phase II	Stage III (unresectable) or stage IV melanoma Treatment-naïve patients Presence of BRAFV600E or V600K mutation in tumor tissue prior to enrolment ECOG PS 0–1 Nivolumab + ipilimumab with nivolumab maintenance or encorafenib + binimetinib for 12 weeks with a switch to nivolumab + ipilimumab with nivolumab maintenance followed by encorafenib + binimetinib at PD	•  PFS	OS CR ORR PFS2Safety